| DIRECT COMPETITOR COMPARISON | |
| ROSG | ALNY | ISIS | MRK | Industry | | Market Cap: | 22.82M | 707.93M | 1.09B | 76.92B | 50.04M | | Employees: | N/A | 175 | 300 | 55,200 | 70 | | Qtrly Rev Growth (yoy): | N/A | -5.80% | -9.10% | 1.80% | 21.40% | | Revenue (ttm): | 1.54M | 98.31M | 118.99M | 23.37B | 12.73M | | Gross Margin (ttm): | 23.54% | -2.31% | -1.31% | 76.36% | 50.41% | | EBITDA (ttm): | -13.66M | -41.20M | -16.09M | 7.81B | -1.76M | | Oper Margins (ttm): | -924.77% | -48.68% | -19.54% | 26.63% | -7.52% | | Net Income (ttm): | -9.45M | -49.19M | -11.27M | 8.05B | N/A | | EPS (ttm): | -0.872 | -1.185 | 1.617 | 3.808 | N/A | | P/E (ttm): | N/A | N/A | 6.83 | 9.58 | 24.44 | | PEG (5 yr expected): | N/A | N/A | 0.24 | 2.43 | 1.25 | | P/S (ttm): | 14.80 | 7.20 | 9.13 | 3.29 | 3.45 |
|
| ALNY = Alnylam Pharmaceuticals, Inc. | | ISIS = Isis Pharmaceuticals, Inc. | | MRK = Merck & Co. Inc. | | Industry = Diagnostic Substances | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.21 | 0.00% | 56.92B | 12.69 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 54.09 | 0.00% | 15.64B | 18.10 | | Genzyme Corp. | GENZ | 54.87 | 0.00% | 14.56B | 31.28 | | Merck Serono S.A. | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.30 | 0.00% | 41.66B | 16.41 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 47.82 | 0.00% | 8.54B | 59.92 | | Teva Pharmaceutical Industries Limited | TEVA | 57.10 | 0.00% | 50.31B | 52.24 | | Sandoz International GmbH | Private - View Profile |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Watson Pharmaceuticals Inc. | WPI | 38.10 | 0.00% | 4.04B | 19.64 | | King Pharmaceuticals Inc. | KG | 11.44 | 0.00% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.68 | 0.00% | 5.40B | 108.47 | | Pfizer Inc. | PFE | 17.88 | 0.00% | 144.28B | 14.85 | | Johnson & Johnson | JNJ | 62.76 | 0.00% | 173.16B | 14.27 | | GlaxoSmithKline plc | GSK | 38.47 | 0.00% | 97.52B | 12.91 | | Sanofi-Aventis | SNY | 36.29 | 0.00% | 94.76B | N/A | | Novartis AG | NVS | 53.58 | 0.00% | 121.69B | 16.04 | | RHHBY.PK | 41.50 | 0.00% | N/A | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | AstraZeneca plc | AZN | 44.11 | 0.00% | 64.00B | 8.50 | | Abbott Laboratories | ABT | 53.35 | 0.00% | 82.52B | 14.44 | | Bristol-Myers Squibb Company | BMY | 24.25 | 0.00% | 48.04B | 4.51 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ISIS | | Genzyme, Isis report positive study on heart drug
Wed 8:24am -
at MarketWatch | | • | ISIS | | ISIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed 8:16am -
EDGAR Online | | • | MRK | | [$$] Markets Make Their Stand
Wed 8:15am -
at RealMoney by TheStreet.com | | • | ISIS | | Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
Wed 7:30am -
Business Wire | | • | MRK | | UPDATE - Sanofi says vaccines to help lift 2010 earnings
Wed 6:21am -
at Reuters | | • | MRK | | Sanofi-Aventis Q4 profit up on swine flu vaccines
Wed 4:59am -
AP | | • | MRK | | [$$] Investors Seek More Disclosure on Political Spending
Tue 6:26pm -
at The Wall Street Journal Online | | • | MRK | | [$$] Caterpillar Tops the Dow
Tue 3:16pm -
at RealMoney by TheStreet.com | | • | ALNY | | Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics
Mon, Feb 8 -
Business Wire | | • | ISIS | | 10 Biotech Stocks on Clinical Trials Watch
Thu, Feb 4 -
at TheStreet.com | | • | ALNY | | Alnylam to Webcast Presentation at The 12th Annual BIO CEO & Investor Conference
Mon, Feb 1 -
Business Wire | | • | ALNY | | Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
Mon, Jan 25 -
Business Wire | | • | ALNY | | The Noble Gesture That Wasn't
Thu, Jan 21 -
at Motley Fool | | • | ALNY | | BIO Ventures for Global Health Chosen as Administrator of Intellectual Property Pool Involving GSK and Alnylam as Participants
Wed, Jan 20 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
1.52% Nasdaq 0.00%
Competitors
